Led · Seed · May 2026

Imagenomix has developed a patent-protected AI platform that identifies genetic alterations of cancer directly from standard histopathology images and maps the spatial distribution of those mutations without DNA sequencing. The company is a New York City–based spinout of NYU Langone Health and is led by CEO Travis Wold. Imagenomix plans to focus initially on lung, brain, and breast cancers. It intends to initiate a clinical trial in breast cancer and to commercially launch a V2 lung cancer classifier later this year in collaboration with Proscia. The firm also supports an alliance with Alterome Therapeutics, which is applying the technology in Phase I therapeutic trials. Financially, Imagenomix recently raised $3.2 million in seed funding to support these development, clinical, and commercial activities.

Participated · Series A · May 2026

Cytospire Therapeutics develops differentiated multispecific engager antibodies that bind and activate both tissue/tumour and blood-resident gamma delta T cells to direct innate and adaptive effector immune responses. Its core technology aims to enable safer and more efficacious targeting of validated antigens that are intractable to CD3 T cell engagers due to toxicity. The company's lead programme, CYT X300, is in IND-enabling preclinical studies while the firm is advancing GMP manufacturing for the asset. Cytospire plans to use its newly raised Series A proceeds to progress this pipeline work. The company is led by CEO Natalie Mount. Recent corporate developments include strengthening the board with appointments from participating investors following the financing.

Participated · Series A · May 2026

Latus Bio develops a gene therapy platform that pairs proprietary and engineered AAV capsids with clinically optimized routes of administration to enable efficient delivery at low doses. The company’s two lead programs are LTS-101 for CLN2 disease, which has IND clearance and multiple FDA designations, and LTS-201 for Huntington’s disease, which is being prepared for IND submission. Latus is advancing capsid variants for potential application beyond CNS disorders, including kidney, eye, heart, and muscle diseases. Management emphasizes scalability and lower-dose delivery to improve safety, manufacturability, and cost, targeting larger rare and broader CNS indications. The company raised $97 million in its Series A (including a $43 million extension) to fund operations through key clinical milestones for these programs.

Participated · Series C · Feb 2026

Brainomix is a University of Oxford spin-out that builds AI medical-imaging software, most notably its fully automated Brainomix 360 Stroke platform for acute stroke assessment and its 360 e-Lung technology that uses CT biomarkers to detect and monitor fibrosing lung disease. The company’s solutions are FDA-cleared, deployed in more than 20 countries, and aim to increase endovascular thrombectomy rates while reducing treatment delays. With offices in the UK, Ireland and the USA, Brainomix already maintains U.S. operations and plans to accelerate hospital roll-outs there. The firm positions its products as workflow-integrated tools that deliver consistent, point-of-care support regardless of local expertise. New capital will be directed toward bolstering customer support, speeding product enhancements, and widening U.S. market penetration. Brainomix cites rigorous clinical validation and real-world evidence underpinning its technology. To date, the company has attracted backing from health- and deep-tech investors focused on AI and life-science innovation.

Participated · Series B · Jan 2026

Founded in 2016 by Drs. Anton Bespalov, Hans Moebius and Rao Vepachedu, Exciva focuses on therapies for neuropsychiatric symptoms in Alzheimer’s disease dementia and related brain disorders. Its lead candidate, Deraphan, combines two CNS-active compounds designed to reduce agitation in Alzheimer’s patients. The company is currently preparing and financing a Phase 2 clinical study to evaluate Deraphan’s therapeutic potential. Exciva leverages proprietary discovery capabilities to identify synergistic compound combinations addressing unmet neuropsychiatric needs. The latest capital infusion strengthens its balance sheet and extends runway through critical mid-stage clinical development. While the company has not disclosed revenue or patient enrollment numbers, the new financing underscores investor confidence in its scientific approach and market opportunity. The refreshed board now includes representatives from key new and existing investors, ensuring broad strategic guidance as the program advances.